drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
Autologous BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy; patient T cells are gene-modified to express a CAR recognizing BCMA (TNFRSF17) to eliminate BCMA+ plasmablasts/plasma cells and some memory B cells, reducing pathogenic autoantibody production.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a CAR targeting BCMA (TNFRSF17). Upon binding BCMA on plasmablasts/plasma cells (and some memory B cells), the CAR T cells activate and kill these cells, depleting antibody-secreting populations and reducing pathogenic autoantibody production.
drug_name
PRG-1801
nct_id_drug_ref
NCT06277427